IP Library Granted Patent US 7,938,821
Granted Patent B2
US 7,938,821 · App. 11/777,965 · Granted May 10, 2011

Apparatus and method for adjustable fractional optical dermatological treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,938,821
App. No.
11/777,965
Granted
May 10, 2011
Kind
B2
Abstract

A fractional treatment system can be configured with a laser wavelength that is selected such that absorption of the laser wavelength within the tissue increases as the tissue is heated by the laser (e.g., 1390-1425 nm). Desirably, the laser wavelength is primarily absorbed within a treated region of skin by water and has a thermally adjusted absorption coefficient within the range of about 8 cm −1 to about 30 cm −1 . An adjustable mechanism can be used to adjust the beam shape, beam numerical aperture, beam focus depth, and/or beam size to affect the treatment depth and or the character of the resulting lesions. The system may be designed to be switchable between a treatment mode that is semi-ablative and a treatment mode that is not semi-ablative. Adjustment of these parameters can improve the efficiency and efficacy of treatment. Illustrative examples of adjustable mechanisms include a set of spacers of different lengths, a rotatable turret with lens elements of different focal distances, an optical zoom lens, and a mechanical adjustment apparatus for adjusting the spacing between two optical lens elements.

Claims (66)

1. An apparatus for fractional dermatological treatment of skin, the apparatus comprising:

a laser source that emits optical energy at a laser wavelength, wherein the absorption of said laser wavelength in water increases as the tissue is heated from 30° C. to 80° C. and said laser wavelength is in the range of 1350 nm to 3000 nm;

a fractional optical delivery system that delivers an optical beam emitted from said laser source to a target area of skin, said fractional optical delivery system comprising an adjustment mechanism that adjusts one or more parameters of said optical beam selected from the group consisting of a size of the optical beam at the skin surface, a focal depth of the optical beam below the skin surface, a numerical aperture of the optical beam as the optical beam enters the skin, and a beam cross-sectional shape at the skin surface; and

a controller that electronically controls said adjustment mechanism, said controller configured to control said adjustment mechanism to switch between a semi-ablative treatment mode for a preselected pulse energy for said optical beam and a treatment mode that is non-semi-ablative for said preselected pulse energy.

2. The apparatus of claim 1 wherein said adjustment mechanism adjusts the size of the optical beam at the surface of the skin.

3. The apparatus of claim 2 wherein said adjustment mechanism is configured to adjust an optical spot size of the optical beam at the surface of the skin to at least one optical spot size within the range of about 50 μm and 120 μm wherein optical spot size is measured to the 1/e 2 intensity level of the optical beam.

4. The apparatus of claim 1 wherein said adjustment mechanism adjusts the focal depth of the optical beam below the surface of the skin.

5. The apparatus of claim 1 wherein said adjustment mechanism adjusts the numerical aperture of the optical beam as the optical beam enters the surface of the skin.

6. The apparatus of claim 1 wherein the laser wavelength is selected with at least one of the characteristics in the group consisting of

a thermally adjusted absorption coefficient of water in the skin is within the range of about 8 cm −1 to about 30 cm −1 ;

a thermally adjusted absorption coefficient of water in the skin is within the range of about 12 cm −1 to about 27 cm −1 ;

a derivative of the absorption for water at 30° C. in the skin with respect to wavelength is less than about 0.7 (cm nm) −1 at the laser wavelength;

a derivative of the absorption for water at 30° C. in the skin with respect to wavelength is

within the range of about 0.3 to about 0.7 (cm nm) −1 at the laser wavelength;

the absorption of the laser wavelength by water in the skin increases by at least 10% as the temperature of water is increased from 30° C. to 80° C.;

the absorption of the laser wavelength by water in the skin increases by about 10% to about 24% as the temperature of water is increased from 30° C. to 80° C.; and

the absorption of the laser wavelength by water in the skin increases by about 16% to about 24% as the temperature of water is increased from 30° C. to 80° C.

7. The apparatus of claim 1 wherein the laser wavelength is selected such that a thermally adjusted absorption coefficient of water in the skin at the laser wavelength is within the range of about 8 cm −1 to about 30 cm −1 , a derivative of the absorption for water at 30° C. in the skin with respect to wavelength is within the range of about 0.3 to about 0.7 (cm nm) −1 at the laser wavelength, and the absorption of the laser wavelength by water in the skin increases by about 10% to about 24% as the temperature of the water is increased from 30° C. to 80° C.

8. The apparatus of claim 1 wherein the laser wavelength is selected such that a thermally adjusted absorption coefficient of water in the skin at the laser wavelength is within the range of about 12 cm −1 to about 27 cm −1 , a derivative of the absorption for water at 30° C. in the skin with respect to wavelength is within the range of about 0.3 to about 0.7 (cm nm) −1 at the laser wavelength, and the absorption of the laser wavelength by water in the skin increases by about 16% to about 24% as the temperature of the water is increased from 30° C. to 80° C.

9. The apparatus of claim 1 wherein the absorption of the laser wavelength by water in the skin increases by about 23% to about 26% as the temperature of water is increased from 30° C. to 80° C.

10. The apparatus of claim 1 wherein the laser wavelength is in the range of about 1390 nm to about 1425 nm.

11. The apparatus of claim 10 wherein said laser source comprises a laser diode.

12. The apparatus of claim 10 wherein said laser source comprises a Raman-shifted ytterbium-doped fiber laser.

13. The apparatus of claim 1 wherein the laser wavelength is in the range of about 1380 nm to about 1420 nm.

14. The apparatus of claim 1 wherein the laser wavelength is in the range of about 1835 nm to about 1920 nm.

15. The apparatus of claim 14 wherein said laser source comprises a thulium fiber laser.

16. The apparatus of claim 14 wherein said laser source comprises a Raman-shifted ytterbium-doped fiber laser.

17. The apparatus of claim 1 wherein said laser wavelength is in the range of about 1835 nm to about 1880 nm.

18. The apparatus of claim 1 wherein said laser wavelength is in the range of about 1880 nm to about 1900 nm.

19. The apparatus of claim 1 wherein the adjustment mechanism includes an adjustable lens group.

20. The apparatus of claim 1 wherein the adjustment mechanism includes discretely interchangeable optical elements.

21. An apparatus for fractional dermatological treatment of skin, the apparatus comprising:

a laser source that emits optical energy at a laser wavelength, wherein the absorption of said laser wavelength in water increases as the tissue is heated from 30° C. to 80° C. and said laser wavelength is in the range of 1350 nm to 3000 nm;

a fractional optical delivery system that delivers an optical beam emitted from said laser source to a target area of skin, said fractional optical delivery system comprising an adjustment mechanism that adjusts one or more parameters of said optical beam selected from the group consisting of a size of the optical beam at the skin surface, a focal depth of the optical beam below the skin surface, a numerical aperture of the optical beam as the optical beam enters the skin, and a beam cross-sectional shape at the skin surface; and

a controller configured to switch the apparatus from a semi-ablative mode to a non-semi-ablative mode by adjusting an adjustable lens group and/or by exchanging interchangeable optical elements.

22. The apparatus of claim 21 wherein said laser wavelength is in the range of about 1390 nm to about 1425 nm.

23. The apparatus of claim 21 wherein the controller is configured to switch the apparatus from the semi-ablative mode to the non-semi-ablative mode by adjusting the adjustable lens group.

24. An apparatus for fractional dermatological treatment of skin, the apparatus comprising:

a laser source that emits optical energy at a laser wavelength, wherein the absorption of said laser wavelength in water increases as the tissue is heated from 30° C. to 80° C. and said laser wavelength is in the range of 1350 nm to 3000 nm;

a fractional optical delivery system that delivers an optical beam emitted from said laser source to a target area of skin, said fractional optical delivery system comprising an adjustment mechanism that adjusts one or more parameters of said optical beam selected from the group consisting of a size of the optical beam at the skin surface, a focal depth of the optical beam below the skin surface, a numerical aperture of the optical beam as the optical beam enters the skin, and a beam cross-sectional shape at the skin surface; and

a user interface that selects between semi-ablative treatment parameters and non-semi-ablative treatment parameters.

25. The apparatus of claim 24 wherein said laser wavelength is in the range of about 1390 nm to about 1425 nm.

26. The apparatus of claim 24 wherein the adjustment mechanism includes an adjustable lens group.

27. The apparatus of claim 24 wherein the adjustment mechanism includes discretely interchangeable optical elements.

28. An apparatus for fractional dermatological treatment of skin, the apparatus comprising:

a laser source that emits an optical beam at a wavelength in the range of about 1390 nm to about 1425 nm and selected from the range such that an absorption in water dynamically increases as the skin is heated from 30° C. to 80° C.;

a fractional optical delivery system that delivers the optical beam emitted from said laser source to a treatment area on the skin, the fractional optical delivery system comprising an adjustment mechanism that adjusts the optical spot size of the optical beam at the skin, and the adjustment mechanism includes an adjustable lens group and/or discretely interchangeable optical elements; and

a controller configured to electronically control said fractional optical delivery system to switch between a first treatment mode that is semi-ablative at a preselected pulse energy for the optical beam and a second treatment mode that is non-semi-ablative for the preselected pulse energy.

29. The apparatus of claim 28 wherein the laser wavelength is in the range of about 1400 nm to about 1420 nm.

30. The apparatus of claim 28 wherein the laser wavelength is about 1410 nm.

31. The apparatus of claim 28 further comprising:

a noncontact tip.

32. The apparatus of claim 28 further comprising:

a contact tip.

33. The apparatus of claim 28 further comprising:

a set of tips comprising at least one noncontact tip and at least one contact tip.

34. An apparatus for fractional dermatological treatment of skin, the apparatus comprising:

a laser source that emits an optical beam at a wavelength in the range of about 1390 nm to about 1425 nm and selected from the range such that an absorption in water dynamically increases as the skin is heated from 30° C. to 80° C.;

a fractional optical delivery system that delivers the optical beam emitted from said laser source to a treatment area on the skin, the fractional optical delivery system comprising an adjustment mechanism that adjusts the optical spot size of the optical beam at the skin, and the adjustment mechanism includes an adjustable lens group and/or discretely interchangeable optical elements; and

a controller configured to electronically switch the apparatus from a semi-ablative mode to a non-semi-ablative mode by adjusting the adjustable lens group and/or by exchanging the interchangeable optical elements.

35. The apparatus of claim 34 wherein the controller is configured to electronically switch the apparatus from the semi-ablative mode to the non-semi-ablative mode by adjusting the adjustable lens group.

36. An apparatus for fractional dermatological treatment of skin, the apparatus comprising:

a laser source that emits an optical beam at a wavelength in the range of about 1390 nm to about 1425 nm and selected from the range such that an absorption in water dynamically increases as the skin is heated from 30° C. to 80° C.;

a fractional optical delivery system that delivers the optical beam emitted from said laser source to a treatment area on the skin, the fractional optical delivery system comprising an adjustment mechanism that adjusts the optical spot size of the optical beam at the skin, and the adjustment mechanism includes an adjustable lens group and/or discretely interchangeable optical elements; and

a controller that electronically controls said fractional optical delivery system; and

a user interface coupled with the controller, the user interface configured to select between semi-ablative treatment parameters and non-semi-ablative treatment parameters.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
MERGER Recorded May 14, 2021
From: RELIANT TECHNOLOGIES, LLC
To: SOLTA MEDICAL, INC.
Reel/Frame 056244/0936 →
MERGER Recorded May 12, 2021
From: RELIANT TECHNOLOGIES, INC.
To: RELIANT TECHNOLOGIES, LLC
Reel/Frame 056218/0067 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →